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Psoriasis is a common skin disease in which retinoids have 
beneficial effects. It offers a model for the study of benign 
hyperproliferation with abno rmal differentiation. The der-
m is h as a prominent rol e in the appearance of epidermal 
lesio ns. It is therefore of interest to study the factors that 
m odulate dermal ce ll proliferation. In this study, the role of 
retinoids in modulating pl atelet-derived growth factor 
(PDGF) bioactivity was studied in normal (six subjects) and 
psoriatic fibrobl as ts from involved and uninvolved tissues 
(s ix patients). 
Retinoic acid treatment (for 4 d at 10-6 M) of psoriatic 
fi broblasts significantl y increased the chemotactic effect of 
P DGF in these cells (p < 0.01 and p < 0 .05, respectively, in 
involved and uninvolved skin at 20 ng/ ml of platelet-
P sori as is is a common skin disease in wh ich retinoids have benefi cial effects. Psoriasis provides a model for the study of benign hyperproliferation with abnormal dif-ferentiation. Psoriasis is thought to be principall y a dis-ease of the epidermis that causes a disruption in the nor-
mal events of keratinocyte maturation and proliferation [1 ,2). 
Recent studies [3,4) offer evidence that the dermis has a prominent 
ro le in the appearance of psoriatic lesions; psoriatic fibrobl asts in-
duce the hyperprolife ration of normal keratinocytes in vitro, sug-
gesting that the primary defect in psoriatic skin may reside in dermal 
fib robl as ts. It is therefore of interest to study the growth properties 
of psoriatic fib roblasts in culture, as well as the factors that modulate 
these growth properti es . 
W e have previously shown that psoriatic, as compared to normal, 
fib robl as ts have increased sensitivity to platelet-derived growth fac-
tor (PDGF) [5). PDGF is a heat-stable basic protein, highly mito-
genic for fibrobl as ts when added to plasma [6 ,7) and is one of the 
major chemotactic agents for these cells [8). PDGF derived from 
human platelets is a disulfide-linked heterodimer consisting of an A 
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derived growth factor as m easured in a modified Boyden 
Chamber Assay). In the same way, retinoic acid treatment of 
psoriatic fibroblasts increased the mitogenicity of platelet-
derived growth factor in these cells . Retinoic acid treatment 
has no significant effect on the mitogenic and chemotactic 
activity of PDGF in normal fibroblasts. 
The binding of the homodimer BB PDGF to its type-B 
receptor, which mediates the mitogenic and chemotactic ef-
fect of PDGF, was not modified by retinoic acid treatment 
either in psoriatic and/or normal fibroblasts. 
These results suggest that retinoic acid may modulate the 
PDGF bioactivity in psoriatic fibroblasts not by affecting the 
binding of this ligand to these cells but by influencing a 
post-receptor event. J Invest Dermatol 96:111 -115, 1991 
and B chain, although there is evidence for the presence of homo-
dimers (AA or BB) from other cell sources (see [9) for review). 
PDGF exerts its biologic activity via binding to specific cell-surface 
receptors [10). Two classes of receptors have recently been de-
scribed, type A and type B [7 - 12) .The type-B receptor is identical 
to the previously identified and cloned PDGF receptor with protein 
tyrosine kinase activity and mediates the mitogenic and chemotactic 
effect ofFDGF [11) . 
In this study, we demonstrate that retinoic acid increases the 
chemotactic and mitogenic effect of PDGF in psoriatic fibroblasts 
without significantly modifying the type-B PDGF receptor number 
or affinity. 
MATERIALS AND METHODS 
Reagents Highly purified PDGF was purchased from Collabora-
tive Research (Lexington , MA) and was also generously supplied by 
Dr. G Grotendorst (Charleston, SC). Dulbecco's modified Eagle's 
medium (DMEM), glutamine, and trypsin were from Flow Labora-
tories (Puteaux, France); fetal calf serum (FCS) was purchased from 
Intermed (Strasbourg, France). Nucleopore filters were from Nu-
cleopore Corporation (Pleasanton, CA). Diff-Quik stain was ob-
tained from Merz + Dade AG (Di.idingen, Switzerland). (3H) thy-
midine (5 cunes/ mmol) .was from Amersham (Les Ulis, France). 
All - trans-v1tamm A (retmo1c ac1d) was generous gift from Hoff-
mann La Roche. 
Cells Human fibrobl as ts were isolated from normal adult and 
untreated adult .patients by enzymatic digestion of smal l pieces 
(4 mm) of skm bwps1es taken from non-l esional and lesional tissues. 
Bi~psy of the non-lesional tissue was taken about 5 em away from a 
leswnal area. The sbn fragments were rinsed twice with 5 ml of 
warm DMEM containing penicillin (50 U/ ml) and streptomycin 
(50 U / ml) . The washed skin samples were minced into small pieces 
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and incubated with trypsin (2.5 mg/ml) in 10 ml of DMEM for 
1 h. The trypsinized skin fragments were recovered by low-speed 
centrifugation (1000 rpm for 3 min) and incubated in DMEM con-
taining collagenase (1 mg/ml) for 1 h, followed by incubation in 
0.5 mg/ml col lagenase for 18 h at 37°C with shaking in a rotatory 
incubator (New Brunswick). Cells were pelleted by centrifugation 
at 400 X g for 10 min, then resuspended in 9 ml of DMEM con-
taining 10% FCS, penicillin (50 U /ml), and streptomycin (50 U / 
ml), and plated onto a 90-mm cell-culture dish. Cells were grown in 
a 5% C02- humidified atmosphere at 3 7 o C and culture medium was 
changed every 3d. At confluence (2.5 106 cells/10-mm dish), cell s 
were removed by trypsin treatment (0.5% trypsin and 0.2% EDTA) 
and 7 X 105 cells were seeded per dish. The cel ls were used after 
their third to sixth passage always at the same density (subcon-
fluent). 
Chemotaxis Assay As previously described [13-15], fibroblasts 
harvested from culture dishes by brief exposure to a solution of 
0.05% trypsin/0 .02% EDT A were suspended in an equal volume of 
DMEM plus 10% fetal calf serum centrifuged at 1000 rpm for 
5 min, and resuspended in the same medium at room temperature 
for 1 h with occasional agitation. The cells were then washed twice 
with serum-free DMEM, and suspended in the same medium at a 
concentration of 1.5 X 106 cell s/mi. 
Blind-well modified Boyden chemotaxis chamber and Nucleo-
pore polycarbonate filters (8,u-diameter pores) were used to measure 
fibroblast chemotaxis. The fi lters were treated with 1% gelatin as 
previously described to promote fibroblast adherence to their upper 
and lower surfaces (1 3]. One hundred fifteen microliters of various 
concentrations ofPDGF diluted in DMEM was placed in the lower 
chamber as attractant. The upper chamber compartments were 
loaded with 200 ,ul of fibroblast suspension (3 X 105 cells). Chemo-
taxis chambers were incubated at 37°C for 150 min in a humidified 
atmosphere containing 5% C02• Filters were then removed from 
the chambers and cells were fixed and stained using Diff-Quik stain 
(AMS, France). The number of cells on the lower surface of the 
filter was determined by counting the number of nuclei in 10 fields 
under a phase-contrast microscope. Chemotaxis assay was per-
formed in duplicate and repeated at least 3 times for each fibroblast 
culture. Checkerboard analysis showed that PDGF has a specific 
chemotactic effect and did not increase random motility. 
Thymidine Incorporation Mitogenic activity was measured as 
previously described (16, 17], with the following modifications. Fi-
broblasts were plated in 96-wcll micro titer plates at 104 cells/well in 
0.2 ml DMEM plus 5% FCS with or without retinoic acid 10-6 M. 
The following day the cells were washed twice with serum-free 
medium and 0.2 ml serum-free DMEM was added for 48 h to re-
duce the basal rate of [3H] thymidine incorporation in the presence 
or absence of lQ-6 M retinoic acid. Aliquots of PDGF at various 
concentrations were added and the cell s were incubated for 20 h 
with or without retinoic acid . C ultures were then incubated for 4 h 
with 0.2 uCi/well (3H] thymidine (5 Ci/mmol) and 5% platelet-
poor plasma again with or without retinoic acid. Platelet-poor 
plasma was prepared as previously described [17). The cells were 
harvested by a cell harvester and filterdisc transfer system (SKA-
TRON A.B, type 7000) samples from triplicate wells were counted 
in Beckman LS 3801 Scintillation Countez· using Readysafe (Beck-
man) as scintill ation fluid. The experiments were repeated twice. 
PDGF Binding Assays (3 X 104 to 12 X 104) fibroblasts were 
plated in 3.5-cm dishes (Costar) and grown for 4 d in the presence 
or absence of retinoic acid (10-6M) before usc. The binding assay 
buffer contained DMEM, HEPES (25 mM, pH 7.4) and 0.1% w /v 
bovine serum albumin (BSA). Cells were incubated with c-sis [1251) 
PDGF (Amcrsham (1000 Ci/Mmol), 50,000 cpm] in 0.7 ml bind-
ing buffer and varying amounts of unlabeled PDGF (from zero to 
100 ngjml). Unlabeled PDGF was csis-recombinant PDGF (ho-
modimer BB) from Amersham. Cells were incubated for 2 h at 
room temperature (21 oq, the binding medium aspirated and dishes 
washed 5 times with ice-cold phosphate-buffered saline (PBS). 
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Cell s were solubilized with 2 X i ml of 0.5 M NaOH and extracts 
counted in a y counter. Normal and psoriatic cells treated or not 
with retinoic acid were at the ·same cell density when used for PDGF 
binding assays. Non-specific binding (measured in presence of 
200 ng/ml of unlabeled PDGF) did not exceed 10% of the total 
binding. 
Retinoic Acid Treatment of Cells Retinoic acid dissolved in 
absolute ethanol was added to give the indicated concentration, 
18 h after cell plating for 4 d. The final concentration of ethanol in 
the medium (0.01 %) did not alter fibroblasts' growth or PDGF 
bioactivity (not shown). 
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Figure 1. Effect of rerinoic-acid treatment on the chemotactic response of 
normal and psoriatic fibroblasts to PDGF. PDGF at the concentrations indi-
cated was added to the lower compartment of a modified Boyden chamber. 
The chemotaxis assay was performed as described in Materials a11d Methods. 
Results are exp~essed as percent of control. The control represents the fi-
broblast mtgratton observed using DMEM in the lower compartment of 
modtfied Boyden chamber. A, results are the mean ± SEM of determina-
tions in six normal fibroblast cultures treated (N + RA) or not (N control) 
with 10-6 M retinoic acid for 4 d; B, mean± SEM of determinations in 
psoriatic fibroblasts cultured from involved skin (ISP) of six patients treated 
(ISP + RA) or nor (ISP control) with 10-6 M retinoic acid for 4 d; C, 
mean± SEM of determinations in psoriatic fibroblasts cultured from unin-
volved skin (UISP) of six patients treated (UISP + RA) or not (UISP con-
trol) with 10- 6 M retinoic acid for 4 d. 
VOL. 96, NO. 1 JANUARY 1991 EFFECT OF RETINOIC ACID ON PDGF ACTIVITY 113 
Table I. Effect of Retinoic-Acid Treatment on the Chemotactic Response of Normal and Psoriatic Fibroblasts to PDGF• 
Maximum Chemotactic Response 
Number of Cells per Filter 
- Retinoic Acid + Retinoic Acid Cutaneous 
Cell Patients Score -PDGF +PDGF % -PDGF +PDGF % 
Normal skin 1 300 810 270 300 1008 336 
2 150 345 230 160 530 330 
3 320 770 240 300 730 242 
4 250 745 298 270 1190 438 
5 300 720 240 280 700 250 
6 200 520 260 180 468 260 
Involved skin 7 25.4 200 600 300 200 1120 560 
8 11 300 960 320 300 1560 520 
9 21.7 300 900 300 300 1440 480 
10 8.5 150 600 400 160 900 560 
11 15 240 720 300 200 1000 500 
12 9 300 900 300 300 1560 520 
Uninvolved skin 7 230 860 344 250 1060 423 
8 300 1090 362 300 1875 625 
9 300 1350 450 300 2490 835 
10 150 645 430 150 975 650 
11 250 875 350 270 1890 700 
12 320 1280 400 300 2238 769 
• Individual values of cutaneous score of the patients and the chemotactic response to 20 ng/ml ofPDGF of the psoriatic and normal fibroblasts cultured 4 din the presence or absence 
of 10--< M retinoic acid. The number of cells on the lower surface of the filter was determined by countin g the number of nuclei in I 0 fields (0.6 mm in diameter) under a 
phase-contrast microscope. The results are the mean of at least three experiments and arc expressed as the number of cells on the entire filter ( 45 mm in diameter). 
RESULTS 
Effect of Retinoic Acid on the Chemotactic Response of 
Psoriatic Fibroblasts We previously showed that PDGF is a 
more potent chemoattractant for psoriatic fibroblasts compared to 
normal [5]. a result reproduced here and clearly visible when com-
paring control curves in the three panels of Fig 1. After 4 d of 
treatment by retinoic acid at 10-6 M, psoriatic fibroblasts have signif-
icantly increased chemotactic response to PDGF compared to un-
treated psoriatic fibroblasts (p < 0.01 and p < 0.05, respectively, in 
involved and uninvolved skin for 20 ng/ml of PDGF) (Fig lB, C; 
Table I). As shown in Fig 2, the effect of retinoic acid on the 
chemotactic response of psoriatic fibroblasts from uninvolved skin 
is dose dependent, with a maximal effect observed at 10-7 M of 
retinoic acid. Similar dose-response effect is observed with psoriatic 
fibroblasts from involved skin (data not shown). 
In contrast, normal fibroblasts treated for 4 d with retinoic acid at 
l0-6 M have a slight but not significant increase in their chemotac-
tic response to PDGF. None of the doses of retinoic acid tested (Fig. 
2) has an effect on the PDGF chemotactic activity. Retinoic acid 
added during the chemotaxis assay has no effect (data not shown) . 
Effect ofRetinoic Acid on the Mitogenic Response ofPsor-
iatic Fibroblasts In order to confirm the increased sensitivity of 
psoriatic fibroblasts to PDGF after retinoic acid treatment, the mi-
togenic effect of this agent was compared among retinoic acid-
treated and untreated psoriatic and normal fibroblasts (Fig 2). 
PDGF in the presence of platelet-poor plasma stimulated the 
incorporation of (3H) thymidine in a dose-dependent manner in 
normal and psoriatic fibroblasts (Fig 3), but PDGF alone in the 
absence of plasma has no effect either in normal or in psoriatic 
fibroblasts (data not shown) . After retinoic acid treatment, psoriatic 
fibroblasts from both involved and uninvolved skin were signifi-
cantly more sensitive to the mitogenic effect of PDGF than un-
treated cells (p < 0.01 and p < 0.01, respectively, in involved and 
uninvolved skin for 20 ng/ml ofPDGF). The dose-response curve 
of the effect of retinoic acid on the mitogenic response of psoriatic 
fibroblasts to PDGF is similar to the one observed when the effect of 
retinoic acid was tested on the chemotactic response (data not 
shown) . In normal fibroblasts, retinoic acid had a slight but not 
significant effect on the mitogenesis induced by PDGF. 
Effect of Retinoic Acid on the PDGF Binding to Psoriatic 
Fibroblasts To test whether enhancement of PDGF mitogenic-
ity in psoriatic fibroblasts by retinoic acid was due to an alteration in 
PDGF binding kinetics, we conducted binding experiments using 
(12SI)- labeled C sis PDGF (homodimer BB). 
PDGF BB binds specifically on the normal and psoriatic fibro-
blasts, with a maximal and equilibrium level at 21 o C occurring at 90 
min (data not shown). Scatchard plot analysis of the binding data 
indicate (Fig 4, Table II) that 4 d of treatment of retinoic acid do not 
modify the number of receptors for PDGF BB in psoriatic cells. The 
affinity of this receptor for PDGF is not changed by retinoic-acid 
treatment. Apparent B-receptor Humbers were found to be in psor-
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Figure 2. Dose-response curve of the effect of retinoic acid on the chemo-
tactic response of psoriatic fibroblasts to PDGF. PDGF at a concentration of 
10 ng/ml was added to the lower compartment of a modified Boyden 
chamber. Fibroblasts from uninvolved skin of two patients were treated for 
4 d in the presence of the indicated concentrations of retinoic acid. The 
chemotaxis assay was performed as described in Materials a11d Methods. Re-
sults are expressed as percent of control. The control represents the migra-
tion of fibroblasts cultured in the absence of retinoic acid, and tested in rhe 
presence of 10 ng/ml of PDGF in the lower compartment of the Boyden 
chamber. Results are the mean± SEM of triplicate determinations of two 
experiments in psoriatic fibroblasts cultured from uninvolved skin of two 
patients or in fibroblasts cultured from two normal subjects. 
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Figure 3. Effect of retinoic-acid treatment on the mitogenic response of 
norma] and psoriatic fibroblasts to PDGF. PDGF at the conccntratw.n mdl-
cated was added to se rum-deprived fibrob lasts (as md1cated 1n Matenals a11d 
Methods), and treated w ith 1Q-6 M of retinoic acid for 4 d. The results are the 
mean± SEM of determinations in triplicate 111: A, SIX normal fibroblast 
cultures treated (N + RA) or not (N control) with 10-6 M retinoic ac id for 
4 d; B,C, psoriatic fibrob last cultures established from Involved (ISP) and 
uninvolved skin (UISP) of six patients and treated (UISP + RA) or not 
(UISP control) for 4 d with 10- 6 M rctinoic acid. 
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Figure 4. Scatchard plot anal ys is of PDGF bindin g to normal fibrob lasts 
(panel A) and psoriatic fibroblasts (pa11ef B) treated (0) with 1Q- 6 M retinoic 
ac id for 4 d; (e), untreated cultures. The experiment illustrated is one of 
three performed in duplicate in fo ur different subjects and giving essentially 
similar resu lts. Confluent cul tures were incubated for 2 hat 21 •c with [1251] 
PDGF in 0. 7 ml binding buffer. Non-specific bindin g was determined as 
that in the presence of excess of unlabeled PDGF (200 ng/ml). 
iatic fibroblasts 73 to 140 X 104 sites per ce ll in the absence of 
retinoic acid and 87 to 190 X 104 sites per cell in the presence of 
retinoic acid. T he binding affinities (Kds) for PDGF in the absence 
and presence of retinoic acid were 1.17 X 1 o-9 M and 1.15 X 10-9 
M, respectively. 
DISCUSSION 
Increasing numbers of in vitro and in vivo experiments are showing 
that the dermis, long considered a passive mechanical support sys-
tem, plays a key ro le in con trolling the growth and differentiation 
of the epidermis . 
In the dermis, the functions of fibroblasts are not only to synthe-
size and degrade the extracellul ar matrix but also to regulate epider-
malization by remodeling the collagen fibers and secreting diffusi-
ble factors that promote epidermal growth (4,18] . 
Psoriasis is a specific human disease that offers a model for study-
ing the regulatory mechanisms involved in a benign hyperprolifera-
Table 11. Effect of Retinoic-Acid Treatment on Type B PDGF Receptors in Normal and Psoriatic Fibroblasts 
- Retinoic Acid + Retinoic Acid 
Cell Patients Sites, Number/Cel l kD 10- 9 M Sires, Number/Cel l kD 10- 9 M 
Normal sk in 1 520,000 1.17 570,000 0.92 
2 800,000 1.28 840,000 1.30 
Involved skin 6 730,000 1.41 870,000 1.70 
7 820,000 1.40 840,000 1.62 
8 1,300,000 0.85 1,900,000 0.70 
9 940,000 0.98 910,000 0.92 
Uninvolved skin 6 890,000 1.2 790,000 0.90 
7 1,200,000 0.96 1,300,000 1.00 
8 1,400,000 0.95 1,279,000 1.49 
9 800,000 1.01 820,000 1.10 
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tion with abnormal differentiation of the epithelium. Recent studies 
[3] offer evidence that dern1is has a prominent role in the appearance 
of p soriatic lesions: psoriatic fibrobl as ts induce the hyperprolifera-
tion of normal keratinocytes in vitro, suggesting that the primary 
defect in psoriatic skin may res ide in dermal fibroblasts. Psoriasis 
thus offers a unique opportunity to study the regulation of growth 
and differentiation of epidermis by dermis. 
We previously showed that psoriatic fibroblasts have increased 
chemotactic and mitogenic responses to PDGF as compared to nor-
mal fibroblasts [5] . The present study confirms these previous re-
sults . In addition, as shown in the fibroblasts of four psoriatic pa-
tients, this increased effect of PDGF does not seem to be related to 
an increase in the PDGF receptor number or affinity (Table II). 
PDGF exerts its mitogenic and chemotactic effect via binding to 
the type-B receptor [ 11]. This receptor is a transmembrane protein 
w ith an external ligand binding domain and an internal domain 
w ith protein tyrosine kinase activity that becomes activated after 
ligand binding [1 9]. Recent studies using PDGF-receptor mutants 
suggest that the internal part of the PDGF receptor with tyrosine 
kinase activity has structural domains responsible for specific func-
tions of the receptor [20]. One of these domains seems essential for 
mitogenesis but not for other cellular responses to POGF such as 
PDGF-stimulated increase in intracellular Ca++, PDGF-stimulated 
conversion of phospho-inositides into inositol phosphates, and 
PDGF-induced change in intracellular pH. An attractive but still 
speculative hypothesis is that psoriasis is a pathologic model in 
which the internal part of the PDGF receptor is modified in one of 
these domains, explaining the increased sensitivity of psoriatic fibro-
blasts to the mitogenic and chemotactic effects of PDGF. 
Of interest is the fact that retinoic acid clearly potentiates the 
mitogenic and chemotactic effect of PDGF in psoriatic fibroblasts 
and has only a sli ght and not significant effect in normal fibroblasts . 
Our data do not reveal a change in the binding kinetics for PDGF in 
the presence of retinoic acid in psoriatic fibrobl as ts. 
These effects of retinoic acid on PDGF action are distinct from its 
interaction with other growth factors such as EGF or interleukin 2. 
Retinoic acid enhances the binding of EGF to numerous cell lines 
[21 ,22] and upregulates the receptors of interleukin 2 on activated 
human thymocytes [23] . 
The results presented in this study suggest that retinoic acid 
might be acting on the internal domain of PDGF receptor with 
protein tyrosine kinase activity or on a post-PDGF receptor event 
such as PDGF-induced protein phosphorylation, hydrolysis of 
membrane phosphatidylinositol (24], increase in intracellular cal-
cium [25], or stimulation of protein kinase C [26]. One of these 
effects could be involved in the mechanism whereby the mitogenic 
and chemotactic signal is transmitted from the activated PDGF 
receptor, and cou ld be the retinoic acid-sensitive event. This in vitro 
potentiation of the PDGF bioactivity on psoriatic fibroblasts by 
retinoic acid is difficult to relate to th e beneficial effect of retinoid 
therapy in actual knowledge of the disease. 
Psoriatic fibroblasts, as well as normal fibroblasts , do not produce 
PDGF as measured by radioreceptor assay (F. Raynaud, unpublished 
results). In addition, retinoic acid does not induce a PDGF secretion 
in psoriatic fibrob lasts (F. Raynaud, unpublished results). These data 
excl ude the fact that an autocrine system for PDGF controls psoria-
tic fibrob last growth. However, endothelial cells [27] and activated 
macrophages [28] produce PDGF, suggesting a paracrine mecha-
nism involved in the stimulation of connective tissue cell mitogenic-
ity and in the inflammatory process in the dermis of psoriatic pa-
tients. 
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